MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Schrodinger Inc

Ouvert

SecteurSoins de santé

26.59 1.76

Résumé

Variation du prix de l'action

24h

Actuel

Min

25.6

Max

26.49

Chiffres clés

By Trading Economics

Revenu

-2.1M

-40M

Ventes

53M

88M

BPA

-0.24

Marge bénéficiaire

-45.536

Employés

891

EBITDA

48M

-19M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+35.9% upside

Dividendes

By Dow Jones

Prochains Résultats

7 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

333M

1.9B

Ouverture précédente

24.83

Clôture précédente

26.59

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Schrodinger Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 nov. 2024, 11:55 UTC

Actualités

Schrödinger's Stock Soars 9% As It Enters Collaboration Pact With Novartis For Up To About $2.5 Billion In Payments -- MarketWatch

Comparaison

Variation de prix

Schrodinger Inc prévision

Objectif de Prix

By TipRanks

35.9% hausse

Prévisions sur 12 Mois

Moyen 34.6 USD  35.9%

Haut 45 USD

Bas 31 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

6

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

25.75 / 26.86Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Very Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.